Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA (NCT06868290)
A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Who can join: Review the eligibility criteria below.
Location: University Of Colorado — Aurora, Colorado
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (35 Sites)
Showing the first 25 of 35 sites.
- University Of Colorado — Aurora, Colorado
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Northwestern University — Chicago, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
- Michigan Med University of Michigan — Ann Arbor, Michigan
- University of Minnesota — Minneapolis, Minnesota
- Mayo Clinic Rochester — Rochester, Minnesota
- Oregon Health Sciences University — Portland, Oregon
- Baylor University Medical Center — Dallas, Texas
- Houston Methodist Hospital — Houston, Texas
- LDS Hospital — Salt Lake City, Utah
- Novartis Investigative Site — Salvador, Estado de Bahia
- Novartis Investigative Site — Barretos, São Paulo
- Novartis Investigative Site — São Paulo, São Paulo
- Novartis Investigative Site — São Paulo,
- Novartis Investigative Site — Haifa,
- Novartis Investigative Site — Ramat Gan,
- Novartis Investigative Site — Sapporo, Hokkaido
- Novartis Investigative Site — Kobe, Hyōgo
- Novartis Investigative Site — Sendai, Miyagi
- Novartis Investigative Site — Suita, Osaka
- Novartis Investigative Site — Bunkyo Ku, Tokyo
- Novartis Investigative Site — Shinjuku-ku, Tokyo
- Novartis Investigative Site — Chiba,
- Novartis Investigative Site — Fukuoka,
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All ANCA Associated Vasculitis (AAV) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.